c-RET

The c-RET proto-oncogene, which was originally identified as a transforming gene by transfection of T-cell lymphoma DNA into NIH3T3 cells, is a member of the receptor tyrosine kinase (RTK) gene superfamily that encodes a receptor tyrosine kinase involved in the regulation of glial cell line-derived neurotrophic factor (GDNF) signaling. Signaling proteins, such as Grb7/Grb10, PLCγ, Shc/Enigma and Grb2, are recruited by activated c-RET protein through binding to the phosphorylated tyrosine residues in c-RET protein’s COOH-terminal sequence, Y905, Y1015, Y1062 and Y1096 respectively.  Moreover, results of in vivo studies suggest mutations of c-RET have been implicated in tumorigenesis, in which c-RET mRNA and/or protein have been found in tumors of neuroectodermal origin as well as in human neuroblastoma cell lines.

Products for c-RET

  1. Cat.No. Product Name Information
  2. BCC1883 Regorafenib hydrochloride
  3. BCC1884 Regorafenib monohydrateTyrosine kinase inhibitor
  4. BCC1974 SU5416VEGFR inhibitor. Also inhibits KIT, RET, MET and FLT3
  5. BCC2172 Danusertib (PHA-739358)Pan-aurora kinase inhibitor
  6. BCC2198 TG101209JAK2/3 inhibitor
  7. BCC2258 Amuvatinib (MP-470, HPK 56)Tyrosine kinase inhibitor
  8. BCC3646 RegorafenibInhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

Items 1 to 7 of 7 total